Multiple clinical trials investigating whether blockade of PD-1/PD-L1 signaling leads to improved outcomes in endometrial cancer have reported promising results suggesting the PD-1/PD-L1 signaling has a key role in endometrial tumor progression (43). Here, CD274 is linked to endometrium neoplasm.